Recent performance snapshot

Novo Nordisk (NYSE:NVO) has drawn attention after a mixed run in the stock, with a gain of about 15% over the past month but a decline of roughly 5% over the past 3 months.

Stepping back from the recent rebound, Novo Nordisk’s 14.8% 1 month share price return contrasts with a weaker year to date move and a 1 year total shareholder return that has declined 31%. This hints at improving short term momentum after a tougher stretch.

If Novo Nordisk’s recent swings have you thinking about where else to put fresh capital to work, this could be a good moment to scan for specialised healthcare AI opportunities using our 34 healthcare AI stocks.

With shares down 31% over the past year and trading at a reported 52% discount to one intrinsic value estimate, a key question arises for investors: Is this genuine value, or is the market already pricing in future growth?

Most Popular Narrative: 52.7% Undervalued

According to the most followed narrative, Novo Nordisk’s last close at $44.96 sits well below an assessed fair value of $95, which frames the recent share price weakness very differently from headline sentiment.

With durable economics, undervalued optionality, and long-duration growth potential, Novo Nordisk stands as a high-quality compounder available at a rare discount. In a market lacking margin resilience, Novo offers both growth and ballast.

Want to see what sits underneath that rare discount label? The narrative leans heavily on long run revenue expansion, resilient profitability and a future earnings multiple that assumes the GLP-1 engine keeps powering on.

Result: Fair Value of $95 (UNDERVALUED)

However, this hinges on GLP-1 competition and policy pressure not biting harder, with tougher pricing, guidance cuts, or weaker Wegovy and Ozempic trends all potential spoilers.

Next Steps

If this mix of concern and optimism feels familiar, use it as a prompt to look at the numbers yourself and decide where you stand, starting with the 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If Novo Nordisk has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target long term compounders by scanning companies that look mispriced on quality and value using the 49 high quality undervalued stocks.
• Prioritise resilience by checking out stocks that pair robust finances with staying power through the 66 resilient stocks with low risk scores.
• Get ahead of the crowd by spotting strong businesses the market has not fully focused on yet via the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.